Since the HIV epidemic began, the diagnosis of HIV has evolved from a death sentence to a chronic, but manageable condition by starting and staying on treatment. HIV treatment can help people live ...

Gilead Sciences has announced a collaboration with the US State Department and the President’s Emergency Plan for AIDS Relief (PEPFAR) to distribute its injectable HIV-1 capsid inhibitor, lenacapavir, ...

As the annual U.S. Conference on HIV/AIDS (USCHA) kicks off in Washington, D.C., this week with a focus on aging with HIV, Gilead Sciences is rolling out a corresponding awareness campaign ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the company announced it had reached an agreement with the Global Fund to Fight Aids, Tuberculosis, ...

Dr. Toyin Nwafor of Gilead Sciences is working at the intersection of medical innovation and community engagement to address persistent disparities in HIV prevention, particularly among Black women.

– Funding Will Reach Under-Resourced Communities Most Impacted by the HIV Epidemic and COVID-19 Pandemic – FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc., (Nasdaq: GILD) today announced ...

– New Data Showcase Safety Profile of Twice-Yearly Lenacapavir for Pre-Exposure Prophylaxis (PrEP) with Other Medications and Recruitment Strategies for PURPOSE 5 – – Five-Year BICSTaR Results Offer ...

MEXICO CITY--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) denounces Gilead Sciences for once again excluding Latin America and the Caribbean (LAC) from affordable access to a groundbreaking HIV ...